The most questions were asked about issues such as accelerated approval and clinical trials, not Gottlieb's ties to industry.
Scott Gottlieb's industry ties and potential for a conflict of interest generated wide-spread discussion upon his nomination as FDA commissioner, but other topics took center stage during his Senate confirmation hearing.
A Pink Sheet analysis of the 60 asked questions by members of the Senate Health, Education, Labor and Pensions Committee...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
